Anavex Scales Up Synthesis of Anavex 2-73 for Phase 1 Alzheimer's Disease Study

Posted By: Anonymous | Posted On: Jan 29,2009 18:30 pm | View: 10 Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) announces the signing of an agreement to scale up the synthesis of ANAVEX 2-73 for its Phase 1 Alzheimer's Disease study, which is scheduled to commence in 2009.Harvey Lalach, the president of Anavex, said this an important step towards the future development of ANAVEX 2-73 and the commencement of clinical trials. Mr. Lalach added that the company is pleased with its "progress to date with the compound, which shows enormous potential to modify and reverse the effects of Alzheimer's disease. We look forward to continued success as we move into our scheduled Phase 1 trials." Read More: http://www.prweb.com/releases/2009/01/prweb1939794.htm